Zydus Therapeutics
Zydus Therapeutics is seeking a strategic and scientifically credible Thought Leader Liaison to build and steward interactions with key hepatology and gastroenterology opinion leaders for the launch of saroglitazar for PBC. The role serves as the primary field interface between the company and its national opinion leader community, focusing on landscape prioritization, scientific consultation, and field activation. This individual contributor role bridges the OL universe with internal commercial teams to translate intelligence into organizational action within a rigorous compliance framework.
Headquarters
Pennington, New Jersey, United States
Zydus Therapeutics is a clinical-stage, specialty-focused biopharmaceutical company dedicated to developing transformative treatments for rare and serious liver diseases. As a subsidiary of Zydus Lifesciences, the company leverages a research team of 1,300 scientists and is currently enrolling patients in two late-stage clinical trials, including studies on Primary Biliary Cholangitis (PBC) and NASH. Its pipeline includes Saroglitazar Mg, which has received FDA Fast Track Designation for PBC treatment.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Zydus Therapeutics.